Drug intelligence / Profile preview

[18F]AlF-NOTA

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
Administration: Intravenous

Overview

[18F]AlF-NOTA is a radiolabeled complex consisting of the positron-emitting radionuclide fluorine-18 ([18F]) coordinated with aluminum (Al3+) and chelated by 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). This complex acts as a stable, pseudo-radiometal platform that can be conjugated to various targeting vectors, such as peptides, small molecules, or antibodies, to create positron emission tomography (PET) imaging tracers. The Al[18F]-NOTA labeling strategy allows for rapid, high-yield, and stable radiolabeling under relatively mild aqueous conditions, making it highly suitable for clinical translation and centralized radiopharmaceutical production.

Other names: 18F-AlF-NOTAAl18F-NOTAAl-18F-NOTAAl 18F-NOTAfluorine F 18-Al-NOTA

Beyond the preview

Go deeper on [18F]AlF-NOTA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]AlF-NOTA.